DDInter626 DDInter625
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients. Treatment options for chronic hepatitis C have advanced significantly since 2011, with the development of direct-acting antivirals (DAAs) such as elbasvir. Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.[synthesis] The barrier to the development of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs. Substitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to elbasvir. Despite this
Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.
Elagolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osilodrostat
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Elagolix {u} may lead to a major life threatening interaction when taken with {v} Rifampicin
Elagolix {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Elagolix may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Elagolix may lead to a major life threatening interaction when taken with Rifampicin
Elagolix may lead to a major life threatening interaction when taken with Tazemetostat